Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Therapeutic Advances in Rare Disease · 2026-03 · 7
DOI: 10.1177/26330040261433035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Rare Disease, online erschienen am 25.03.2026. Verfasst von Arif Mitha und 4 weiteren Autor:innen. Beteiligte Einrichtung: 20Sense, Toronto, ON, Canada. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Real-World Evidence and Outcomes-Based Agreements Working Group, abbvie, amgen.
Abstract (Originalsprache)
Background
Outcome-based agreements (OBAs) may facilitate earlier patient access to promising therapies, particularly when evidence is limited. The authors of this paper investigated how to operationalize an OBA using real-world data (RWD) from the Canadian Neuromuscular Disease Registry (CNDR).
Objective
The first objective of this research was to determine which spinal muscular atrophy (SMA) health outcomes in the CNDR are suitable for an OBA. The second objective was to evaluate the current process of data collection in the CNDR and explore how to operationalize data processes to support an OBA, including identifying gaps and proposing solutions.
Design
This qualitative expert-led assessment was conducted through a series of focus group discussions with selected experts.
Methods
A selected group of experts participated in 17 focus group meetings. The ability of the CNDR to generate real-world evidence (RWE) for an OBA was evaluated for eight SMA health outcomes. The criteria used were data readiness, interpretability, and timeframe within the CNDR. Next, the processes involved were evaluated, specifically to determine how data tracking within the CNDR could be operationalized for an OBA, including identifying gaps and possible solutions. Based on the findings, the group proposed a future state for an OBA process using the CNDR. The group followed up with stakeholder feedback interviews to validate the findings of this research and to gather insights.
Results
Five SMA outcomes within the CNDR were identified as potentially suitable outcomes for OBA. Three process gaps were identified in the current state of the CNDR, and corresponding solutions were proposed. A proposed future-state process flow for CNDR was developed to support RWE generation for OBA.
Conclusions
Expert consultations suggest that operationalizing an OBA using CNDR RWD is feasible.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 20Sense, Toronto, ON, Canada.
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
- Cure SMA Canada Society, Chilliwack, BC, Canada.
- EVERSANA Life Science Services LLC, Chicago, IL, USA.
ORCID-Profile: Arif Mitha, Allison Wills
Förderung
- Real-World Evidence and Outcomes-Based Agreements Working Group
- abbvie
- amgen
- astrazeneca
- Janssen
- pfizer
- roche
Zitieren
APA
Mitha, A., Hodgkinson, V., Vander Wyk, S., Cameron, C., & Wills, A. (2026). Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy. Therapeutic Advances in Rare Disease, 7. https://doi.org/10.1177/26330040261433035
Vancouver
Mitha A, Hodgkinson V, Vander Wyk S, Cameron C, Wills A. Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy. Therapeutic Advances in Rare Disease. 2026;7. doi:10.1177/26330040261433035
BibTeX
@article{Mitha2026,
author = {Mitha, Arif and Hodgkinson, Victoria and Vander Wyk, Susi and Cameron, Chris and Wills, Allison},
title = {Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy},
journal = {Therapeutic Advances in Rare Disease},
year = {2026},
volume = {7},
doi = {10.1177/26330040261433035}
}
EUVIMED